Correia CE, Schaff LR, Grommes C (2020) Central nervous system lymphoma: approach to diagnosis and treatment. Cancer J 26:241–252. https://doi.org/10.1097/ppo.0000000000000449

Article  CAS  PubMed  Google Scholar 

Enblad G, Martinsson G, Baecklund E, Hesselager G, Sundström C, Amini RM, Hagberg H (2017) Population-based experience on primary central nervous system lymphoma 2000–2012: the incidence is increasing. Acta Oncol 56:599–607. https://doi.org/10.1080/0284186x.2016.1270465

Article  PubMed  Google Scholar 

Reni M, Ferreri AJ, Guha-Thakurta N, Blay JY, Dell’Oro S, Biron P, Hochberg FH (2001) Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate. Int J Radiat Oncol Biol Phys 51:419–425. https://doi.org/10.1016/s0360-3016(01)01639-x

Article  CAS  PubMed  Google Scholar 

Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G (2016) Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 3:e217-227. https://doi.org/10.1016/s2352-3026(16)00036-3

Article  PubMed  Google Scholar 

Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, Cabras MG, Fabbri A, Corazzelli G, Ilariucci F, Rossi G, Soffietti R, Stelitano C, Vallisa D, Zaja F, Zoppegno L, Aondio GM, Avvisati G, Balzarotti M, Brandes AA, Fajardo J, Gomez H, Guarini A, Pinotti G, Rigacci L, Uhlmann C, Picozzi P, Vezzulli P, Ponzoni M, Zucca E, Caligaris-Cappio F, Cavalli F (2009) High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 374:1512–1520. https://doi.org/10.1016/s0140-6736(09)61416-1

Article  CAS  PubMed  Google Scholar 

Bonzheim I, Sander P, Salmerón-Villalobos J, Süsskind D, Szurman P, Gekeler F, Spitzer MS, Steinhilber J, Kohler E, Büssgen M, Schittenhelm J, Salaverria I, Campo E, Coupland SE, Quintanilla-Martinez L, Fend F (2022) The molecular hallmarks of primary and secondary vitreoretinal lymphoma. Blood Adv 6:1598–1607. https://doi.org/10.1182/bloodadvances.2021004212

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ollila TA, Olszewski AJ (2018) Extranodal diffuse large B cell lymphoma: Molecular features, prognosis, and risk of central nervous system recurrence. Curr Treat Options Oncol 19:38. https://doi.org/10.1007/s11864-018-0555-8

Article  PubMed  PubMed Central  Google Scholar 

Cetin GO, Baris IC, Caner V, Sarikepe B, Sen Turk N, Tepeli E, Hacioglu S, Sari I, Bagci G, Keskin A (2016) Mutational status of EZH2 and CD79B hot spots in mature B-cell non-Hodgkin’s lymphomas: novel CD79B variations have been revealed. Eur Rev Med Pharmacol Sci 20:830–836

CAS  PubMed  Google Scholar 

Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, Hodson DJ, Xiao W, Yu X, Yang Y, Zhao H, Xu W, Liu X, Zhou B, Du W, Chan WC, Jaffe ES, Gascoyne RD, Connors JM, Campo E, Lopez-Guillermo A, Rosenwald A, Ott G, Delabie J, Rimsza LM, Tay Kuang Wei K, Zelenetz AD, Leonard JP, Bartlett NL, Tran B, Shetty J, Zhao Y, Soppet DR, Pittaluga S, Wilson WH, Staudt LM (2018) Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med 378:1396–1407. https://doi.org/10.1056/NEJMoa1801445

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen F, Pang D, Guo H, Ou Q, Wu X, Jiang X, Wei X, Liu S, Huang L, Liang Z, Zhou D, Li W (2020) Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: a real-world experience of off-label ibrutinib use. Cancer Med 9:8676–8684. https://doi.org/10.1002/cam4.3499

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, Yang Y, Cole DE, Melani C, Higham CS, Desai JV, Ceribelli M, Chen L, Thomas CJ, Little RF, Gea-Banacloche J, Bhaumik S, Stetler-Stevenson M, Pittaluga S, Jaffe ES, Heiss J, Lucas N, Steinberg SM, Staudt LM, Wilson WH (2017) Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell 31:833-843.e835. https://doi.org/10.1016/j.ccell.2017.04.012

Article  CAS  PubMed  PubMed Central  Google Scholar 

Renaud L, Bossard JB, Carpentier B, Terriou L, Cambier N, Chanteau G, Escure G, Tilmont R, Barbieux S, Wemeau M, Hieulle J, Boyle EM, Morschhauser F (2021) Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). Eur J Haematol 107:370–373. https://doi.org/10.1111/ejh.13667

Article  CAS  PubMed  Google Scholar 

Lewis KL, Chin CK, Manos K, Casey J, Hamad N, Crawford J, Ho SJ, Issa S, Grigg A, Wood P, Gandhi MK, Do B, Nastoupil L, Hawkes EA, Cheah CY (2021) Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience. Br J Haematol 192:1049–1053. https://doi.org/10.1111/bjh.16946

Article  CAS  PubMed  Google Scholar 

Soussain C, Choquet S, Blonski M, Leclercq D, Houillier C, Rezai K, Bijou F, Houot R, Boyle E, Gressin R, Nicolas-Virelizier E, Barrie M, Moluçon-Chabrot C, Lelez ML, Clavert A, Coisy S, Leruez S, Touitou V, Cassoux N, Daniau M, Ertault de la Bretonnière M, El Yamani A, Ghesquières H, Hoang-Xuan K (2019) Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II “proof-of-concept” iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. Eur J Cancer 117:121–130. https://doi.org/10.1016/j.ejca.2019.05.024

Article  CAS  PubMed  Google Scholar 

Song Y, Xu W, Song Y, Liu L, Lin S, Li Z, Liu T, Yi S, Zhou D, Zhang M, Hu Y, Jin J, Zhu H, Lu Z, Zhao R, Xu Z, Zhu J (2020) Pooled analysis of safety data from clinical trials of orelabrutinib monotherapy in hematologic malignancies. Blood 136:43–43. https://doi.org/10.1182/blood-2020-140172

Article  Google Scholar 

Zhang B, Zhao R, Liang R, Gao Y, Liu R, Chen X, Lu Z, Wang Z, Yu L, Shakib S, Cui J (2020) Abstract CT132: Orelabrutinib, a potent and selective Bruton’s tyrosine kinase inhibitor with superior safety profile and excellent PK/PD properties. Cancer Res 80:CT132–CT132. https://doi.org/10.1158/1538-7445.Am2020-ct132

Article  Google Scholar 

Yu H, Wang X, Li J, Ye Y, Wang D, Fang W, Mi L, Ding N, Wang X, Song Y, Zhu J (2021) Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma. Mol Ther Oncolytics 21:158–170. https://doi.org/10.1016/j.omto.2021.03.015

Article  CAS  PubMed  PubMed Central  Google Scholar 

Holdhoff M, Ambady P, Abdelaziz A, Sarai G, Bonekamp D, Blakeley J, Grossman SA, Ye X (2014) High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology 83:235–239. https://doi.org/10.1212/wnl.0000000000000593

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kansara R, Shenkier TN, Connors JM, Sehn LH, Savage KJ, Gerrie AS, Villa D (2015) Rituximab with high-dose methotrexate in primary central nervous system lymphoma. Am J Hematol 90:1149–1154. https://doi.org/10.1002/ajh.24204

Article  CAS  PubMed  Google Scholar 

Ly KI, Crew LL, Graham CA, Mrugala MM (2016) Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: a single-institution experience. Oncol Lett 11:3471–3476. https://doi.org/10.3892/ol.2016.4393

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yuan X, Yu T, Huang Y, Jiang H, Xu X, Liang Y, Qian W (2022) Rituximab with high-dose methotrexate is effective and cost-effective in newly diagnosed primary central nervous system lymphoma. Sci Rep 12:21541. https://doi.org/10.1038/s41598-022-24922-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ferreri AJM, Calimeri T, Cwynarski K, Dietrich J, Grommes C, Hoang-Xuan K, Hu LS, Illerhaus G, Nayak L, Ponzoni M, Batchelor TT (2023) Primary central nervous system lymphoma. Nat Rev Dis Primers 9:29. https://doi.org/10.1038/s41572-023-00439-0

Article  PubMed  PubMed Central  Google Scholar 

Mendez JS, Ostrom QT, Gittleman H, Kruchko C, DeAngelis LM, Barnholtz-Sloan JS, Grommes C (2018) The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro Oncol 20:687–694. https://doi.org/10.1093/neuonc/nox187

Article  PubMed  Google Scholar 

Hernández-Verdin I, Kirasic E, Wienand K, Mokhtari K, Eimer S, Loiseau H, Rousseau A, Paillassa J, Ahle G, Lerintiu F, Uro-Coste E, Oberic L, Figarella-Branger D, Chinot O, Gauchotte G, Taillandier L, Marolleau JP, Polivka M, Adam C, Ursu R, Schmitt A, Barillot N, Nichelli L, Lozano-Sánchez F, Ibañez-Juliá MJ, Peyre M, Mathon B, Abada Y, Charlotte F, Davi F, Stewart C, de Reyniès A, Choquet S, Soussain C, Houillier C, Chapuy B, Hoang-Xuan K, Alentorn A (2023) Molecular and clinical diversity in primary central nervous system lymphoma. Ann Oncol 34:186–199. https://doi.org/10.1016/j.annonc.2022.11.002

Article  CAS  PubMe